RxDoctor Payments Data

Franklin Fleischhauer, MD

Cardiovascular Disease · Pensacola, FLNPI 1275533788

Payments from drug & device makers

$228,508in general payments, 2019–2025

Across 478 payments — averaging $478.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$62K
  • Boehringer Ingelheim$46K
  • Lilly USA, LLC$39K
  • Boston Scientific$34K
  • Sanofi-aventis U.S. LLC$25K
  • Amgen$12K
  • plus $12K from 28 others

What the payments were for

  • Speaking & faculty fees$138,52790%
  • Travel & lodging$4,7483%
  • Food & beverage$11,4157%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$228,508 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$138,653
Medicare patients
749
Services billed
1,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban280$350,587
Repatha SureclickEvolocumab185$196,719
EntrestoSacubitril/Valsartan114$170,987
JardianceEmpagliflozin55$55,554
XareltoRivaroxaban30$47,367
NexletolBempedoic Acid29$24,490
Praluent PenAlirocumab18$24,138
VascepaIcosapent Ethyl22$18,881
LivaloPitavastatin Calcium18$10,883
Metoprolol Succinate575$10,485
Ezetimibe340$9,380
Icosapent Ethyl17$8,296
Rosuvastatin Calcium451$7,743
Ranolazine ErRanolazine50$6,998
Losartan Potassium531$6,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$437$350,587280 claims
NovartisEntresto$61,516$170,987114 claims
Boehringer IngelheimJardiance$45,743$55,55455 claims
Johnson & JohnsonXarelto$309$47,36730 claims
Esperion Therapeutics, Inc.Nexletol$273$24,49029 claims
Kowa Pharmaceuticals America, Inc.Livalo$89$10,88318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →